United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

reckitt benckiser healthcare (uk) ltd - ibuprofen lysine - oral tablet - 684mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

reckitt benckiser healthcare (uk) ltd - dichlorobenzyl alcohol; amylmetacresol - lozenge - 1.2mg ; 600microgram

India - English - Central Drugs Standard Control Organization

bharat s. - hydroxyethyl starch - (130/0.4)6.00gm,0.90gm(sod. chl.) - 500ml

India - English - Central Drugs Standard Control Organization

bharat s. - hydroxyethyl starch - (200/0.5)6.00gm,0.90gm(sod. chl.) - 500ml

Singapore - English - HSA (Health Sciences Authority)

reckitt benckiser (singapore) pte ltd - ibuprofen acid 400 mg eqv ibuprofen lysine - tablet, film coated - 684mg - ibuprofen acid 400 mg eqv ibuprofen lysine 684mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

rb (health) malaysia sdn bhd - ibuprofen lysine -

Malta - English - Medicines Authority

reckitt benckiser healthcare international limited thane road, nottingham ng90 2db, united kingdom - amylmetacresol, dichlorobenzyl alcohol - lozenge - amylmetacresol 0.6 mg 2,4 dichlorobenzyl alcohol 1.2 mg - throat preparations

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pahang pharmacy sdn. bhd. - sodium citrate anhydrous; citric acid anhydrous; tartaric acid; sodium bicarbonate -

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - pyridostigmine bromide (unii: kvi301na53) (pyridostigmine - unii:19qm69hh21) - pyridostigmine bromide 180 mg - pyridostigmine bromide extended-release tablets are contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. care should be observed in the use of atropine for counteracting side effects, as discussed below.

United States - English - NLM (National Library of Medicine)

alvogen inc. - rivastigmine (unii: pki06m3iw0) (rivastigmine - unii:pki06m3iw0) - rivastigmine 4.6 mg - rivastigmine transdermal system is indicated for the treatment of dementia of the alzheimer’s type (ad). efficacy has been demonstrated in patients with mild, moderate, and severe alzheimer’s disease. rivastigmine transdermal system is indicated for the treatment of mild-to-moderate dementia associated with parkinson’s disease (pdd). rivastigmine transdermal system is contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation [see description (11)] . - previous history of application site reactions with rivastigmine transdermal patch suggestive of allergic contact dermatitis [see warnings and precautions (5.3)] . isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . risk summary   there are no adequate data on the developmental risks associated with the use of rivastigmine transdermal system in pregnant women. in animals, no adverse effects on embryo-